Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ohr Pharmaceutical has received a new US patent no 7,728,157 that includes claims related to a method of synthesis used in the development of its Evizon therapeutic agent for the treatment of Wet-Age-related macular degeneration (AMD), among other compounds.
Subscribe to our email newsletter
The new patent is titled ‘Regioselective and Stereoselective Oxidation of Fused Ring Systems Useful for the Preparation of Aminosterols’. It marks the first patent issued for this intellectual property and it expires in 2023.
Irach Taraporewala, CEO of Ohr Pharmaceutical, said: “Our new synthesis method is not only more cost-effective, but is also more scalable. It shortens the manufacturing process by eliminating steps and the need for purification. Manufacturing advances and the intellectual property surrounding them not only add value to the company’s efforts towards US FDA approval, but also create additional barriers to competition.
“This new patent strengthens our position as we continue development of our two later stage lead drugs, Evizon and OHR/AVR 118 for the treatment of Cancer Cachexia, a severe wasting disorder associated with late stage cancer patients. We look forward to continuing this development and bringing our pipeline of drugs to market.”